Merus N.V Key Executives
This section highlights Merus N.V's key executives, including their titles and compensation details.
Find Contacts at Merus N.V
(Showing 0 of )
Merus N.V Earnings
This section highlights Merus N.V's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Financial Statements
Access annual & quarterly financial statements for Merus N.V, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $36.13M | $43.95M | $41.59M | $49.11M | $29.94M |
| Cost of Revenue | $- | $- | $11.98M | $86.27M | $57.33M |
| Gross Profit | $36.13M | $43.95M | $29.60M | $-37.16M | $-27.39M |
| Gross Profit Ratio | 100.00% | 100.00% | 71.19% | -75.67% | -91.48% |
| Research and Development Expenses | $225.37M | $140.66M | $149.42M | $98.19M | $70.04M |
| General and Administrative Expenses | $82.83M | $59.84M | $52.20M | $40.90M | $35.78M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $82.83M | $59.84M | $52.20M | $40.90M | $35.78M |
| Other Expenses | $- | $- | $1.06M | $-1.14M | $- |
| Operating Expenses | $308.20M | $200.49M | $201.62M | $139.08M | $105.82M |
| Cost and Expenses | $308.20M | $200.49M | $201.62M | $139.08M | $105.82M |
| Interest Income | $- | $14.51M | $2.72M | $113.34K | $300.00K |
| Interest Expense | $- | $- | $2.72M | $129.00K | $- |
| Depreciation and Amortization | $2.47M | $2.54M | $1.28M | $1.49M | $1.44M |
| EBITDA | $-269.60M | $-154.01M | $-148.26M | $-77.75M | $-60.93M |
| EBITDA Ratio | -746.12% | -350.44% | -356.51% | -158.32% | -203.49% |
| Operating Income | $-272.07M | $-156.55M | $-160.04M | $-89.98M | $-75.88M |
| Operating Income Ratio | -752.96% | -356.22% | -384.84% | -183.22% | -253.41% |
| Total Other Income Expenses Net | $64.89M | $4.80M | $19.22M | $12.48M | $-22.90M |
| Income Before Tax | $-207.18M | $-151.75M | $-130.24M | $-66.58M | $-85.01M |
| Income Before Tax Ratio | -573.37% | -345.30% | -313.17% | -135.58% | -283.91% |
| Income Tax Expense | $8.15M | $3.19M | $959.00K | $239.00K | $503.00K |
| Net Income | $-215.33M | $-154.94M | $-131.19M | $-66.82M | $-85.51M |
| Net Income Ratio | -595.93% | -352.56% | -315.48% | -136.06% | -285.59% |
| EPS | $-3.35 | $-3.00 | $-2.92 | $-1.73 | $-2.92 |
| EPS Diluted | $-3.35 | $-3.00 | $-2.92 | $-1.73 | $-2.92 |
| Weighted Average Shares Outstanding | 64.22M | 51.61M | 44.92M | 38.64M | 29.26M |
| Weighted Average Shares Outstanding Diluted | 64.22M | 51.61M | 44.92M | 38.64M | 29.26M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.14M | $11.77M | $7.33M | $7.89M | $8.94M | $11.03M | $10.48M | $13.50M | $10.67M | $6.58M | $12.68M | $11.65M | $14.71M | $13.67M | $12.38M | $8.35M | $9.02M | $8.57M | $6.06M | $6.30M |
| Cost of Revenue | $- | $- | $- | $607.00K | $36.85M | $34.82M | $25.93M | $32.14M | $327.00K | $43.17M | $29.68M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit | $9.14M | $11.77M | $7.33M | $7.28M | $-27.91M | $-23.79M | $-15.46M | $-18.64M | $10.34M | $-36.59M | $-17.00M | $11.65M | $14.71M | $13.67M | $12.38M | $8.35M | $9.02M | $8.57M | $6.06M | $6.30M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 92.31% | -312.27% | -215.59% | -147.54% | -138.11% | 96.93% | -556.04% | -134.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research and Development Expenses | $74.43M | $63.24M | $49.12M | $38.58M | $40.69M | $36.81M | $28.30M | $34.87M | $49.05M | $42.31M | $31.10M | $26.98M | $26.75M | $26.02M | $24.61M | $20.81M | $21.81M | $17.54M | $13.71M | $16.99M |
| General and Administrative Expenses | $23.37M | $20.77M | $22.59M | $16.11M | $15.80M | $12.59M | $16.06M | $15.39M | $15.28M | $12.47M | $12.70M | $11.75M | $10.82M | $10.17M | $10.57M | $9.33M | $9.72M | $9.14M | $8.04M | $8.88M |
| Selling and Marketing Expenses | $- | $- | $-640.00K | $-607.00K | $-618.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $23.37M | $20.77M | $21.95M | $15.51M | $15.18M | $12.59M | $16.06M | $15.39M | $15.28M | $12.47M | $12.70M | $11.75M | $10.82M | $10.17M | $10.57M | $9.33M | $9.72M | $9.14M | $8.04M | $8.88M |
| Other Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $601.00K | $458.00K | $-675.00K | $-75.00K | $52.00K | $-437.00K | $- | $- | $- | $- |
| Operating Expenses | $97.79M | $84.00M | $71.07M | $54.09M | $55.86M | $49.40M | $44.36M | $50.25M | $64.33M | $54.78M | $43.79M | $38.73M | $37.57M | $36.19M | $35.18M | $30.14M | $31.53M | $26.67M | $21.75M | $25.87M |
| Cost and Expenses | $97.79M | $84.00M | $71.71M | $54.70M | $56.48M | $49.40M | $44.36M | $50.25M | $64.33M | $54.78M | $43.79M | $38.73M | $37.57M | $36.19M | $35.18M | $30.14M | $31.53M | $26.67M | $21.75M | $25.87M |
| Interest Income | $- | $10.25M | $7.13M | $- | $5.20M | $4.52M | $2.79M | $2.00M | $1.43M | $866.00K | $- | $- | $- | $- | $- | $- | $- | $- | $99.00K | $280.00K |
| Interest Expense | $- | $- | $- | $- | $12.52M | $- | $- | $2.00M | $1.43M | $866.00K | $316.00K | $106.00K | $29.00K | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $-1.88M | $635.00K | $640.00K | $607.00K | $618.00K | $659.00K | $675.00K | $588.00K | $312.00K | $300.00K | $322.00K | $351.00K | $320.00K | $384.00K | $383.00K | $398.00K | $408.00K | $370.00K | $342.00K | $324.00K |
| EBITDA | $-88.06M | $-96.29M | $-59.50M | $-46.20M | $-46.92M | $-35.67M | $-30.43M | $-36.16M | $-53.35M | $-48.88M | $-29.38M | $-24.15M | $-22.55M | $-19.11M | $-18.90M | $-18.25M | $-22.10M | $-15.12M | $-13.66M | $-17.46M |
| EBITDA Ratio | -963.49% | -817.98% | -811.45% | -585.65% | -524.94% | -323.29% | -290.51% | -267.90% | -500.20% | -742.70% | -231.66% | -207.24% | -153.27% | -139.82% | -152.71% | -218.52% | -245.14% | -176.47% | -225.62% | -277.13% |
| Operating Income | $-88.65M | $-72.23M | $-64.37M | $-46.81M | $-47.54M | $-21.89M | $-33.88M | $-36.75M | $-53.66M | $-48.20M | $-31.11M | $-27.07M | $-22.86M | $-22.52M | $-22.80M | $-21.79M | $-22.51M | $-18.10M | $-15.70M | $-19.57M |
| Operating Income Ratio | -969.93% | -613.59% | -877.99% | -593.35% | -531.85% | -198.44% | -323.45% | -272.26% | -503.12% | -732.34% | -245.25% | -232.29% | -155.45% | -164.75% | -184.20% | -260.95% | -249.67% | -211.25% | -259.18% | -310.55% |
| Total Other Income Expenses Net | $59.49M | $-24.70M | $12.37M | $13.45M | $-16.05M | $14.40M | $513.21K | $-3.45M | $-31.47M | $24.89M | $24.11M | $5.69M | $5.81M | $4.58M | $-8.10M | $8.48M | $-9.34M | $-7.46M | $-3.98M | $1.35M |
| Income Before Tax | $-29.16M | $-96.93M | $-47.73M | $-33.36M | $-59.12M | $-21.89M | $-30.54M | $-40.20M | $-81.58M | $-24.29M | $-5.58M | $-18.78M | $-14.28M | $-14.86M | $-27.33M | $-10.11M | $-27.77M | $-22.90M | $-17.94M | $-16.40M |
| Income Before Tax Ratio | -319.08% | -823.38% | -650.91% | -422.84% | -661.33% | -198.44% | -291.51% | -297.79% | -764.91% | -369.06% | -44.02% | -161.12% | -97.10% | -108.74% | -220.74% | -121.02% | -307.96% | -267.19% | -296.28% | -260.32% |
| Income Tax Expense | $1.76M | $2.98M | $2.32M | $1.10M | $1.04M | $1.12M | $1.49M | $-457.00K | $387.00K | $327.00K | $131.00K | $114.00K | $139.00K | $-11.00K | $62.00K | $49.00K | $198.00K | $177.00K | $31.00K | $97.00K |
| Net Income | $-30.92M | $-99.91M | $-50.04M | $-34.46M | $-60.15M | $-23.01M | $-32.03M | $-39.74M | $-81.97M | $-24.61M | $-5.71M | $-18.89M | $-14.42M | $-14.85M | $-27.39M | $-10.15M | $-27.96M | $-23.07M | $-17.97M | $-16.50M |
| Net Income Ratio | -338.33% | -848.67% | -682.52% | -436.76% | -672.93% | -208.57% | -305.78% | -294.40% | -768.54% | -374.03% | -45.05% | -162.10% | -98.04% | -108.66% | -221.25% | -121.60% | -310.16% | -269.25% | -296.80% | -261.86% |
| EPS | $-0.48 | $-1.46 | $-0.81 | $-0.59 | $-1.04 | $-0.43 | $-0.66 | $-0.86 | $-1.77 | $-0.53 | $-0.13 | $-0.43 | $-0.46 | $-0.39 | $-0.71 | $-0.28 | $-0.96 | $-0.79 | $-0.62 | $-0.57 |
| EPS Diluted | $-0.48 | $-1.46 | $-0.81 | $-0.59 | $-1.04 | $-0.43 | $-0.66 | $-0.86 | $-1.77 | $-0.53 | $-0.13 | $-0.43 | $-0.36 | $-0.39 | $-0.71 | $-0.28 | $-0.96 | $-0.79 | $-0.62 | $-0.57 |
| Weighted Average Shares Outstanding | 64.22M | 68.25M | 61.85M | 58.09M | 57.83M | 53.87M | 48.32M | 46.32M | 46.31M | 46.06M | 43.64M | 43.49M | 31.43M | 38.51M | 38.38M | 36.21M | 29.06M | 29.06M | 29.03M | 28.95M |
| Weighted Average Shares Outstanding Diluted | 64.22M | 68.25M | 61.85M | 58.09M | 57.83M | 53.87M | 48.32M | 46.32M | 46.31M | 46.06M | 43.64M | 43.49M | 40.61M | 38.51M | 38.38M | 36.21M | 29.06M | 29.06M | 29.03M | 28.95M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $293.29M | $205.05M | $147.75M | $241.44M | $163.08M |
| Short Term Investments | $243.73M | $150.13M | $142.48M | $168.99M | $44.67M |
| Cash and Short Term Investments | $537.03M | $355.18M | $290.23M | $410.43M | $207.75M |
| Net Receivables | $4.71M | $3.98M | $4.70M | $6.67M | $1.75M |
| Inventory | $- | $- | $9.31M | $4.91M | $7.43M |
| Other Current Assets | $27.34M | $9.66M | $11.52M | $7.08M | $8.49M |
| Total Current Assets | $569.07M | $368.81M | $306.44M | $424.18M | $217.99M |
| Property Plant Equipment Net | $20.02M | $23.50M | $24.84M | $7.28M | $8.02M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $1.68M | $1.80M | $1.95M | $2.35M | $2.84M |
| Goodwill and Intangible Assets | $1.68M | $1.80M | $1.95M | $2.35M | $2.84M |
| Long Term Investments | $187.01M | $57.31M | $36.46M | $20.30M | $- |
| Tax Assets | $1.52M | $1.20M | $2.04M | $417.00K | $410.00K |
| Other Non-Current Assets | $3.39M | $2.87M | $4.81M | $2.08M | $1.95M |
| Total Non-Current Assets | $213.62M | $86.68M | $70.10M | $32.42M | $13.22M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $782.69M | $455.49M | $376.54M | $456.60M | $231.22M |
| Account Payables | $4.16M | $4.60M | $9.83M | $13.24M | $3.13M |
| Short Term Debt | $1.70M | $1.67M | $1.68M | $1.49M | $1.43M |
| Tax Payables | $7.32M | $1.65M | $2.40M | $- | $206.00K |
| Deferred Revenue | $17.91M | $22.68M | $29.42M | $34.66M | $20.18M |
| Other Current Liabilities | $-13.19M | $38.48M | $35.59M | $22.51M | $21.80M |
| Total Current Liabilities | $17.91M | $69.09M | $78.93M | $71.90M | $46.75M |
| Long Term Debt | $8.21M | $10.49M | $11.79M | $2.26M | $2.52M |
| Deferred Revenue Non-Current | $- | $19.57M | $38.77M | $66.24M | $79.69M |
| Deferred Tax Liabilities Non-Current | $2.44M | $- | $3.37M | $1.06M | $1.11M |
| Other Non-Current Liabilities | $-8.21M | $- | $- | $- | $- |
| Total Non-Current Liabilities | $2.44M | $30.06M | $50.56M | $68.50M | $82.21M |
| Other Liabilities | $114.42M | $- | $- | $- | $- |
| Total Liabilities | $134.77M | $99.15M | $129.49M | $140.40M | $128.95M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $6.96M | $5.88M | $4.75M | $4.48M | $3.21M |
| Retained Earnings | $- | $-753.06M | $-598.12M | $-466.93M | $-400.11M |
| Accumulated Other Comprehensive Income Loss | $- | $-22.53M | $-30.45M | $-9.22M | $9.07M |
| Other Total Stockholders Equity | $194.47M | $1.13B | $870.87M | $787.87M | $490.09M |
| Total Stockholders Equity | $201.43M | $356.34M | $247.06M | $316.20M | $102.26M |
| Total Equity | $201.43M | $356.34M | $247.06M | $316.20M | $102.26M |
| Total Liabilities and Stockholders Equity | $782.69M | $455.49M | $376.54M | $456.60M | $231.22M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $782.69M | $455.49M | $376.54M | $456.60M | $231.22M |
| Total Investments | $430.74M | $207.44M | $178.94M | $189.29M | $44.67M |
| Total Debt | $9.91M | $12.16M | $13.47M | $3.75M | $3.95M |
| Net Debt | $-283.38M | $-192.88M | $-134.28M | $-237.68M | $-159.13M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $293.29M | $433.00M | $629.48M | $178.17M | $205.05M | $241.87M | $101.10M | $102.64M | $147.75M | $190.98M | $213.93M | $194.57M | $241.44M | $159.12M | $311.47M | $327.14M | $163.08M | $139.18M | $152.09M | $165.80M |
| Short Term Investments | $243.73M | $199.27M | $157.95M | $159.33M | $150.13M | $146.70M | $163.95M | $138.60M | $142.48M | $160.46M | $162.18M | $164.24M | $168.99M | $150.62M | $41.28M | $47.25M | $44.67M | $51.02M | $45.28M | $48.23M |
| Cash and Short Term Investments | $537.03M | $632.27M | $787.42M | $337.50M | $355.18M | $388.57M | $265.05M | $241.24M | $290.23M | $351.44M | $376.11M | $358.81M | $410.43M | $309.74M | $352.75M | $374.38M | $207.75M | $190.20M | $197.37M | $214.03M |
| Net Receivables | $4.71M | $3.88M | $3.90M | $60.42M | $3.98M | $4.61M | $3.81M | $5.61M | $4.70M | $3.15M | $4.37M | $3.17M | $6.67M | $3.60M | $3.69M | $1.95M | $1.75M | $2.29M | $2.11M | $1.72M |
| Inventory | $- | $- | $- | $1 | $1 | $10.26M | $12.22M | $8.90M | $9.31M | $12.66M | $15.73M | $15.32M | $4.91M | $5.25M | $9.18M | $8.42M | $7.43M | $6.95M | $8.29M | $7.82M |
| Other Current Assets | $27.34M | $30.12M | $15.23M | $12.35M | $9.66M | $11.65M | $14.27M | $11.31M | $11.52M | $13.61M | $18.35M | $17.75M | $7.08M | $6.38M | $10.55M | $9.79M | $8.29M | $8.82M | $11.93M | $9.70M |
| Total Current Assets | $569.07M | $666.28M | $806.55M | $410.26M | $368.81M | $404.83M | $283.12M | $258.16M | $306.44M | $368.20M | $398.82M | $379.73M | $424.18M | $319.72M | $366.99M | $386.12M | $217.99M | $201.32M | $211.40M | $225.45M |
| Property Plant Equipment Net | $20.02M | $22.46M | $22.38M | $22.10M | $23.50M | $23.50M | $25.00M | $25.71M | $24.84M | $19.68M | $19.77M | $6.84M | $7.28M | $7.59M | $8.36M | $7.27M | $8.02M | $8.02M | $8.15M | $8.39M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $1.68M | $1.86M | $1.66M | $1.72M | $1.80M | $1.77M | $1.88M | $1.93M | $1.95M | $1.89M | $2.08M | $2.23M | $2.35M | $2.47M | $2.61M | $2.65M | $2.84M | $2.78M | $2.73M | $2.74M |
| Goodwill and Intangible Assets | $1.68M | $1.86M | $1.66M | $1.72M | $1.80M | $1.77M | $1.88M | $1.93M | $1.95M | $1.89M | $2.08M | $2.23M | $2.35M | $2.47M | $2.61M | $2.65M | $2.84M | $2.78M | $2.73M | $2.74M |
| Long Term Investments | $187.01M | $150.62M | $58.96M | $61.17M | $57.31M | $57.26M | $46.50M | $46.10M | $36.46M | $21.48M | $20.69M | $25.47M | $20.30M | $23.49M | $- | $- | $- | $- | $- | $- |
| Tax Assets | $1.52M | $838.00K | $543.00K | $277.00K | $4.20M | $702.00K | $3.06M | $2.37M | $2.04M | $435.00K | $241.00K | $80.00K | $417.00K | $219.00K | $140.00K | $41.00K | $410.00K | $291.00K | $210.00K | $111.00K |
| Other Non-Current Assets | $3.39M | $2.63M | $2.13M | $2.56M | $2.87M | $4.12M | $4.06M | $4.24M | $4.81M | $3.31M | $3.19M | $3.15M | $2.08M | $2.43M | $1.48M | $1.87M | $1.95M | $1.08M | $1.17M | $1.27M |
| Total Non-Current Assets | $213.62M | $178.40M | $85.67M | $87.82M | $89.68M | $87.35M | $80.50M | $80.36M | $70.10M | $46.79M | $45.97M | $37.77M | $32.42M | $36.20M | $12.59M | $11.82M | $13.22M | $12.18M | $12.26M | $12.51M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $782.69M | $844.68M | $892.23M | $498.08M | $458.49M | $492.19M | $363.62M | $338.52M | $376.54M | $414.99M | $444.79M | $417.50M | $456.60M | $355.93M | $379.58M | $397.95M | $231.22M | $213.49M | $223.66M | $237.96M |
| Account Payables | $4.16M | $6.18M | $4.39M | $7.49M | $4.60M | $3.84M | $7.60M | $4.99M | $9.83M | $3.12M | $6.96M | $5.39M | $13.24M | $5.40M | $6.16M | $3.71M | $3.13M | $4.72M | $2.36M | $3.38M |
| Short Term Debt | $1.70M | $3.52M | $3.38M | $1.67M | $1.67M | $3.21M | $3.22M | $1.59M | $3.37M | $3.74M | $2.66M | $2.98M | $2.99M | $3.01M | $3.19M | $2.26M | $1.43M | $3.07M | $2.90M | $2.79M |
| Tax Payables | $7.32M | $4.88M | $1.60M | $1.82M | $1.65M | $137.00K | $1.35M | $2.27M | $2.40M | $- | $- | $- | $- | $- | $- | $- | $206.00K | $- | $- | $- |
| Deferred Revenue | $29.93M | $30.97M | $32.35M | $34.14M | $22.68M | $23.02M | $24.15M | $26.70M | $29.42M | $27.98M | $30.71M | $33.70M | $34.66M | $37.10M | $32.12M | $25.75M | $20.18M | $19.36M | $18.57M | $18.63M |
| Other Current Liabilities | $43.96M | $34.52M | $39.14M | $33.36M | $38.48M | $34.10M | $29.53M | $39.54M | $33.91M | $29.32M | $19.93M | $19.46M | $21.01M | $26.02M | $22.93M | $21.23M | $21.80M | $18.28M | $14.48M | $10.77M |
| Total Current Liabilities | $87.08M | $80.08M | $80.86M | $78.49M | $69.09M | $64.32M | $65.85M | $75.09M | $78.93M | $64.15M | $60.26M | $61.52M | $71.90M | $71.53M | $64.41M | $52.95M | $46.75M | $45.43M | $38.31M | $35.57M |
| Long Term Debt | $8.21M | $9.28M | $9.33M | $9.85M | $10.49M | $10.51M | $11.17M | $11.59M | $11.79M | $11.27M | $12.29M | $1.87M | $2.26M | $2.65M | $3.20M | $2.40M | $2.52M | $2.74M | $3.12M | $3.48M |
| Deferred Revenue Non-Current | $39.48M | $52.05M | $55.26M | $60.30M | $19.57M | $23.97M | $29.20M | $34.32M | $38.77M | $40.79M | $45.63M | $56.63M | $66.24M | $75.98M | $92.89M | $106.06M | $79.69M | $80.83M | $81.93M | $84.33M |
| Deferred Tax Liabilities Non-Current | $- | $- | $-9.33M | $-9.85M | $3.00M | $-10.51M | $-11.17M | $-11.59M | $-11.79M | $-11.27M | $-12.29M | $-1.87M | $-57.54M | $-63.81M | $-70.75M | $-73.70M | $1.11M | $-83.23M | $-84.59M | $-87.54M |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-1.11M | $- | $- | $- |
| Total Non-Current Liabilities | $47.69M | $61.34M | $64.59M | $70.15M | $33.06M | $34.48M | $40.37M | $45.91M | $50.56M | $52.06M | $57.92M | $58.50M | $68.50M | $78.62M | $96.09M | $108.46M | $82.21M | $83.56M | $85.05M | $87.81M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $134.77M | $141.41M | $145.46M | $148.63M | $102.15M | $98.80M | $106.22M | $121.00M | $129.49M | $116.21M | $118.18M | $120.03M | $140.40M | $150.16M | $160.50M | $161.41M | $128.95M | $128.99M | $123.36M | $123.38M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $6.96M | $6.92M | $6.86M | $5.97M | $5.88M | $5.87M | $5.10M | $4.75M | $4.75M | $4.75M | $4.71M | $4.49M | $4.48M | $3.98M | $3.96M | $3.94M | $3.21M | $2.94M | $2.94M | $2.93M |
| Retained Earnings | $-968.39M | $-937.46M | $-837.56M | $-787.52M | $-753.06M | $-692.91M | $-669.90M | $-637.86M | $-598.12M | $-516.15M | $-491.54M | $-485.82M | $-466.93M | $-452.51M | $-437.65M | $-410.27M | $-400.11M | $-372.15M | $-349.07M | $-331.10M |
| Accumulated Other Comprehensive Income Loss | $- | $-7.12M | $-38.90M | $-29.92M | $-22.53M | $-37.43M | $-26.71M | $-26.21M | $-30.45M | $-54.66M | $-35.19M | $-15.27M | $-9.22M | $-2.24M | $3.15M | $-320.00K | $9.07M | $5.09M | $680.00K | $-1.52M |
| Other Total Stockholders Equity | $1.61B | $1.64B | $1.62B | $1.16B | $1.13B | $1.12B | $948.91M | $876.84M | $870.87M | $864.84M | $848.62M | $794.07M | $787.87M | $656.54M | $649.63M | $643.18M | $490.09M | $448.62M | $445.75M | $444.27M |
| Total Stockholders Equity | $647.93M | $703.26M | $746.77M | $349.45M | $356.34M | $393.39M | $257.40M | $217.52M | $247.06M | $298.78M | $326.61M | $297.47M | $316.20M | $205.77M | $219.09M | $236.54M | $102.26M | $84.50M | $100.30M | $114.59M |
| Total Equity | $647.93M | $703.26M | $746.77M | $349.45M | $356.34M | $393.39M | $257.40M | $217.52M | $247.06M | $298.78M | $326.61M | $297.47M | $316.20M | $205.77M | $219.09M | $236.54M | $102.26M | $84.50M | $100.30M | $114.59M |
| Total Liabilities and Stockholders Equity | $782.69M | $844.68M | $892.23M | $498.08M | $458.49M | $492.19M | $363.62M | $338.52M | $376.54M | $414.99M | $444.79M | $417.50M | $456.60M | $355.93M | $379.58M | $397.95M | $231.22M | $213.49M | $223.66M | $237.96M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $782.69M | $844.68M | $892.23M | $498.08M | $458.49M | $492.19M | $363.62M | $338.52M | $376.54M | $414.99M | $444.79M | $417.50M | $456.60M | $355.93M | $379.58M | $397.95M | $231.22M | $213.49M | $223.66M | $237.96M |
| Total Investments | $430.74M | $349.89M | $216.91M | $220.50M | $207.44M | $146.70M | $163.95M | $138.60M | $178.94M | $181.94M | $182.87M | $189.71M | $189.29M | $174.11M | $41.28M | $47.25M | $44.67M | $51.02M | $45.28M | $48.23M |
| Total Debt | $9.91M | $1.76M | $11.02M | $11.53M | $12.16M | $12.11M | $12.78M | $13.18M | $13.47M | $13.14M | $13.62M | $3.37M | $3.75M | $4.15M | $4.79M | $3.53M | $3.95M | $4.27M | $4.57M | $4.88M |
| Net Debt | $-283.38M | $-431.24M | $-618.46M | $-166.64M | $-192.88M | $-229.75M | $-88.32M | $-89.46M | $-134.28M | $-177.84M | $-200.31M | $-191.21M | $-237.68M | $-154.97M | $-306.68M | $-323.61M | $-159.13M | $-134.91M | $-147.52M | $-160.92M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-215.33M | $-154.94M | $-131.19M | $-66.82M | $-85.51M |
| Depreciation and Amortization | $2.47M | $2.54M | $1.28M | $1.49M | $1.44M |
| Deferred Income Tax | $-321.00K | $842.00K | $-1.62M | $-7.00K | $-122.00K |
| Stock Based Compensation | $45.83M | $26.23M | $24.54M | $17.09M | $9.37M |
| Change in Working Capital | $24.32M | $-25.75M | $-18.97M | $15.87M | $-14.08M |
| Accounts Receivables | $1.07M | $1.73M | $1.83M | $-4.99M | $1.15M |
| Inventory | $- | $- | $- | $1.03M | $4.13M |
| Accounts Payables | $-136.00K | $-3.93M | $-3.92M | $10.71M | $-110.00K |
| Other Working Capital | $23.38M | $-23.55M | $-16.88M | $9.11M | $-19.25M |
| Other Non Cash Items | $-42.81M | $8.88M | $-23.93M | $-27.25M | $9.00M |
| Net Cash Provided by Operating Activities | $-185.84M | $-142.21M | $-149.90M | $-59.63M | $-79.90M |
| Investments in Property Plant and Equipment | $-1.67M | $-3.98M | $-7.64M | $-870.00K | $-1.29M |
| Acquisitions Net | $- | $52.00K | $52.00K | $128.06M | $162.90K |
| Purchases of Investments | $-410.19M | $-235.26M | $-219.72M | $-215.84M | $-66.84M |
| Sales Maturities of Investments | $191.80M | $212.22M | $230.17M | $70.09M | $66.65M |
| Other Investing Activities | $-163.00K | $-52.00K | $-52.00K | $-128.06M | $-162.90K |
| Net Cash Used for Investing Activities | $-220.22M | $-27.02M | $2.80M | $-146.62M | $-1.49M |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $457.48M | $225.94M | $57.74M | $265.11M | $38.07M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $36.53M | $4.14M | $999.00K | $16.85M | $1.45M |
| Net Cash Used Provided by Financing Activities | $494.01M | $230.09M | $58.74M | $281.95M | $39.52M |
| Effect of Forex Changes on Cash | $1.07M | $-4.28M | $-4.95M | $2.76M | $7.34M |
| Net Change in Cash | $89.02M | $56.58M | $-93.31M | $78.47M | $-34.53M |
| Cash at End of Period | $294.03M | $205.01M | $148.44M | $241.75M | $163.28M |
| Cash at Beginning of Period | $205.01M | $148.44M | $241.75M | $163.28M | $197.81M |
| Operating Cash Flow | $-185.84M | $-142.21M | $-149.90M | $-59.63M | $-79.90M |
| Capital Expenditure | $-1.67M | $-3.98M | $-7.64M | $-870.00K | $-1.29M |
| Free Cash Flow | $-187.50M | $-146.19M | $-157.54M | $-60.50M | $-81.19M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-30.92M | $-99.91M | $-50.04M | $-34.46M | $-60.15M | $-23.01M | $-32.03M | $-39.74M | $-81.97M | $-24.61M | $-5.71M | $-18.89M | $-14.42M | $-14.85M | $-27.39M | $-10.15M | $-27.96M | $-23.07M | $-17.97M | $-16.50M |
| Depreciation and Amortization | $589.00K | $635.00K | $640.00K | $607.00K | $618.00K | $659.00K | $675.00K | $588.00K | $312.00K | $300.00K | $322.00K | $351.00K | $320.00K | $384.00K | $383.00K | $398.00K | $408.00K | $370.00K | $342.00K | $324.00K |
| Deferred Income Tax | $-684.00K | $-287.58K | $-268.62K | $923.00K | $-511.45K | $2.35M | $-687.00K | $-328.00K | $-1.60M | $-195.00K | $-161.00K | $337.00K | $-197.00K | $-80.00K | $-99.00K | $369.00K | $-120.00K | $-80.00K | $-99.00K | $177.00K |
| Stock Based Compensation | $15.86M | $13.49M | $11.69M | $4.79M | $6.71M | $7.32M | $6.45M | $5.75M | $6.01M | $6.53M | $6.66M | $5.33M | $4.80M | $4.33M | $4.56M | $3.40M | $3.04M | $2.84M | $1.19M | $2.29M |
| Change in Working Capital | $1.71M | $-23.09M | $52.00M | $-6.49M | $966.29K | $-3.39M | $-15.16M | $-7.85M | $2.26M | $-4.43M | $9.23M | $-26.03M | $-8.89M | $-6.38M | $-6.21M | $37.35M | $-4.89M | $3.86M | $-4.36M | $-8.69M |
| Accounts Receivables | $-223.00K | $792.57K | $57.11M | $-56.59M | $1.11M | $-681.00K | $1.91M | $-631.00K | $-1.20M | $1.02M | $-1.53M | $3.55M | $-3.27M | $379.00K | $-1.76M | $-340.00K | $515.00K | $-47.00K | $-411.00K | $1.09M |
| Inventory | $- | $- | $- | $- | $5.92M | $6.12M | $-12.04M | $- | $- | $- | $- | $- | $-3.42M | $3.10M | $1.80M | $-444.00K | $1.36M | $6.66M | $1.69M | $-5.57M |
| Accounts Payables | $-1.66M | $1.56M | $-3.06M | $3.04M | $601.86K | $-3.64M | $2.61M | $-3.45M | $5.15M | $-3.00M | $1.57M | $-7.63M | $8.15M | $-623.00K | $2.43M | $756.00K | $-1.70M | $2.19M | $-985.00K | $386.00K |
| Other Working Capital | $3.60M | $-25.44M | $-2.05M | $47.06M | $-746.42K | $-5.18M | $-7.64M | $-3.77M | $-1.68M | $-2.45M | $9.20M | $-21.95M | $-10.35M | $-9.23M | $-8.69M | $37.38M | $-5.06M | $-4.93M | $-4.65M | $-4.60M |
| Other Non Cash Items | $-53.22M | $28.73M | $-49.31M | $49.80M | $17.49M | $-11.45M | $-833.00K | $4.84M | $44.48M | $-18.84M | $-42.08M | $-7.49M | $-13.21M | $-6.48M | $4.46M | $-12.02M | $5.18M | $4.38M | $2.29M | $-2.86M |
| Net Cash Provided by Operating Activities | $-66.66M | $-80.42M | $5.79M | $-44.39M | $-34.89M | $-27.53M | $-41.59M | $-36.74M | $-30.51M | $-41.26M | $-31.73M | $-46.40M | $-31.60M | $-23.07M | $-24.30M | $19.34M | $-24.34M | $-11.70M | $-18.61M | $-25.26M |
| Investments in Property Plant and Equipment | $-20.00K | $-114.15K | $-1.47M | $-63.00K | $73.94K | $-39.00K | $-349.00K | $-3.62M | $-2.11M | $-2.33M | $-2.86M | $-342.00K | $-333.00K | $-277.00K | $-103.00K | $-157.00K | $-429.00K | $-346.00K | $-364.00K | $-148.00K |
| Acquisitions Net | $- | $- | $- | $- | $-18.94M | $-7.62M | $22.15M | $4.41M | $52.00K | $-1.21M | $-6.60M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-114.88M | $-196.54M | $-39.94M | $-58.83M | $-28.56M | $-59.71M | $-79.15M | $-65.23M | $-49.03M | $-50.69M | $-64.86M | $-55.14M | $-11.38M | $-179.61M | $-4.21M | $-20.64M | $-17.49M | $-20.41M | $-11.86M | $-17.09M |
| Sales Maturities of Investments | $37.20M | $63.11M | $44.68M | $46.81M | $26.68M | $67.77M | $54.98M | $60.44M | $52.00M | $51.88M | $71.78M | $54.52M | $-4.04M | $45.97M | $10.04M | $18.13M | $23.82M | $14.65M | $14.93M | $13.25M |
| Other Investing Activities | $- | $-163.00K | $- | $-11.14M | $1 | $7.62M | $-22.15M | $-4.41M | $-52.00K | $1.21M | $6.60M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $-77.70M | $-133.71M | $3.27M | $-12.08M | $-1.81M | $8.02M | $-24.52M | $-8.41M | $856.00K | $-1.14M | $4.05M | $-967.00K | $-15.76M | $-133.92M | $5.73M | $-2.67M | $5.90M | $-6.11M | $2.71M | $-3.99M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $-38.38M | $434.86M | $22.61M | $-1.25M | $162.15M | $63.80M | $217.00K | $-1.00K | $9.96M | $48.02M | $- | $119.23M | $- | $-170.00K | $146.04M | $38.07M | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $8.07M | $10.89M | $10.03M | $5.33M | $-1.25M | $253.00K | $-3.34M | $217.00K | $-214.00K | $-81.00K | $184.00K | $879.00K | $7.81M | $2.60M | $2.03M | $4.41M | $38.77M | $22.00K | $127.00K | $438.00K |
| Net Cash Used Provided by Financing Activities | $8.07M | $10.89M | $443.00M | $30.16M | $-1.25M | $162.40M | $65.97M | $217.00K | $-215.00K | $9.88M | $48.20M | $879.00K | $127.04M | $2.60M | $1.86M | $150.46M | $38.77M | $22.00K | $291.00K | $438.00K |
| Effect of Forex Changes on Cash | $-3.45M | $6.75M | $-2.46M | $222.00K | $-636.00K | $-2.13M | $-1.34M | $-171.00K | $-13.82M | $10.04M | $-799.00K | $-377.00K | $2.74M | $2.05M | $1.04M | $-3.07M | $3.57M | $4.87M | $1.90M | $-3.00M |
| Net Change in Cash | $-139.74M | $-195.70M | $451.31M | $-26.88M | $-36.82M | $140.76M | $-1.48M | $-45.10M | $-43.69M | $-22.48M | $19.72M | $-46.86M | $82.43M | $-152.35M | $-15.66M | $164.06M | $23.90M | $-12.91M | $-13.71M | $-31.81M |
| Cash at End of Period | $294.03M | $433.77M | $629.48M | $178.17M | $205.05M | $242.62M | $101.86M | $103.33M | $148.44M | $192.13M | $214.61M | $194.89M | $241.75M | $159.32M | $311.67M | $327.34M | $163.28M | $139.38M | $152.29M | $166.00M |
| Cash at Beginning of Period | $433.77M | $629.48M | $178.17M | $205.05M | $241.87M | $101.86M | $103.33M | $148.44M | $192.13M | $214.61M | $194.89M | $241.75M | $159.32M | $311.67M | $327.34M | $163.28M | $139.38M | $152.29M | $166.00M | $197.81M |
| Operating Cash Flow | $-66.66M | $-80.58M | $5.79M | $-44.39M | $-34.89M | $-27.53M | $-41.59M | $-36.74M | $-30.51M | $-41.26M | $-31.73M | $-46.40M | $-31.60M | $-23.07M | $-24.30M | $19.34M | $-24.34M | $-11.70M | $-18.61M | $-25.26M |
| Capital Expenditure | $-20.00K | $-114.15K | $-1.47M | $-63.00K | $73.94K | $-39.00K | $-349.00K | $-3.62M | $-2.11M | $-2.33M | $-2.86M | $-342.00K | $-333.00K | $-277.00K | $-103.00K | $-157.00K | $-429.00K | $-346.00K | $-364.00K | $-148.00K |
| Free Cash Flow | $-66.68M | $-80.69M | $4.32M | $-44.45M | $-34.81M | $-27.57M | $-41.94M | $-40.36M | $-32.62M | $-43.59M | $-34.59M | $-46.74M | $-31.93M | $-23.35M | $-24.40M | $19.19M | $-24.77M | $-12.04M | $-18.97M | $-25.41M |
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
$45.05
Stock Price
$3.11B
Market Cap
260
Employees
Utrecht, None
Location
Revenue (FY 2024)
$36.13M
-17.8% YoY
Net Income (FY 2024)
$-215.33M
-39.0% YoY
EPS (FY 2024)
$-3.35
-11.7% YoY
Free Cash Flow (FY 2024)
$-187.50M
-28.3% YoY
Profitability
Gross Margin
100.0%
Net Margin
-595.9%
ROE
-106.9%
ROA
-27.5%
Valuation
P/E Ratio
-12.54
P/S Ratio
74.74
EV/EBITDA
-8.97
Market Cap
$3.11B
Revenue & Net Income
Profit Margins
Cash Flow Summary
Operating Cash Flow
$-185.84M
-30.7% YoY
Free Cash Flow
$-187.50M
-28.3% YoY
Balance Sheet Summary
Total Assets
$782.69M
71.8% YoY
Total Debt
$9.91M
18.5% YoY
Shareholder Equity
$201.43M
46.1% YoY
Dividend Overview
No Dividend Data
Merus N.V. doesn't currently pay dividends.
Merus N.V Dividends
Explore Merus N.V's dividend history, including dividend yield, payout ratio, and historical payments.
Merus N.V News
Read the latest news about Merus N.V, including recent articles, headlines, and updates.
Merus: Riding The Bispecific Wave In Oncology
Merus stands out in biotech with its innovative Biclonics and Multiclonics platforms, focusing on bispecific and multispecific antibodies, particularly petosemtamab. Strong financials with $724 million cash runway through 2028, allowing strategic R&D investments without immediate capital market pressures. Petosemtamab shows robust clinical data, receiving two FDA Breakthrough Therapy designations, indicating significant potential in treating HNSCC and other cancers.
Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025 at 8:45 a.m. ET.
Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update
- Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling; expected to be substantially enrolled by YE25
New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the New England Journal of Medicine (NEJM) published results of the registrational phase 2 eNRGy trial for Bizengri® (zenocutuzumab), the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell lung cancer (NSCLC) that are advanced unresectable or metastatic and harbor a neuregulin 1 (NRG1) gene fusion who have disease progression on or after prior systemic therapy.
Time To Upgrade Merus N.V. To A 'Buy' After The Recent Selloff
Bizengri's recent approval gives MRUS the first approved therapy for NRG1+ cancers, which, I think, will be a valuable niche. Petosemtamab's recent Phase 2 data for HNSCC suggests it could also have blockbuster potential as long as its Phase 3 trials are successful as well. I also like MRUS's recent partnership with BHVN as it gives it optionality with new ADC programs that could have oncology applications.
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs
NEW HAVEN, Conn. and UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Biohaven Ltd. (NYSE: BHVN) and Merus N.V. (Nasdaq:MRUS), today announced a research collaboration and license agreement to co-develop three novel bispecific antibody drug conjugates (ADCs), leveraging Merus' leading Biclonics® technology platform, and Biohaven's next-generation ADC conjugation and payload platform technologies.
Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®) for cancer, today announced that the first patient has been dosed in the Company's phase 2 trial evaluating petosemtamab monotherapy in heavily pretreated (3L+) metastatic colorectal cancer (mCRC). Petosemtamab is a Biclonics® targeting EGFR and LGR5.
Merus Scores Its First FDA Approval For Lung Cancer Drug
On Wednesday, the FDA approved Merus N.V.'s MRUS Bizengri (zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell lung cancer (NSCLC) that are advanced unresectable or metastatic and harbor a neuregulin 1 (NRG1) gene fusion who have disease progression on or after prior systemic therapy.
Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) [Merus, the Company, we, or our], a clinical-stage oncology company developing innovative, full-length, multispecific antibodies (Biclonics® and Triclonics®), announced today that the U.S. Food and Drug Administration (FDA) approved BIZENGRI® (zenocutuzumab-zbco), the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell lung cancer (NSCLC) that are advanced unresectable or metastatic and harbor a neuregulin 1 (NRG1) gene fusion who have disease progression on or after prior systemic therapy. These indications are approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). BIZENGRI® has a Boxed WARNING for Embryo-Fetal Toxicity and warnings for infusion-related reactions (IRRs), hypersensitivity and anaphylactic reactions, interstitial lung disease (ILD)/pneumonitis, and left ventricular dysfunction.1 See Important Safety Information below.
Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®) and Partner Therapeutics, Inc. (PTx), a private, fully-integrated biotechnology company with a focus in hematology and oncology, today announced they have entered into an agreement in which Merus has exclusively licensed to PTx the right to commercialize zenocutuzumab (Zeno) for the treatment of NRG1 fusion-positive (NRG1+) cancer in the United States (U.S.).
Merus: Petosemtamab Set Up For December 2024 Data Presentation
Merus is nearing a major milestone with zenocutuzumab's potential FDA approval for NRG1+ NSCLC/PDAC, with a PDUFA date of February 4, 2025. Petosemtamab, targeting 1st and 2nd-line HNSCC, shows promise with updated data to be presented at ESMO Asia Congress in December 2024. Financially stable with $782.9 million in cash, Merus has strategic partnerships with Gilead, Eli Lilly, Incyte, and Ono Pharmaceutical, funding operations into 2028.
Merus Receives FDA extension of PDUFA for zenocutuzumab
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the United States Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for zenocutuzumab (Zeno) Biologics License Application (BLA) currently under priority review.
Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the third quarter and provided a business update.
Merus: Great European Oncology Developer, But Properly Valued
Merus NV has seen a significant increase in market cap from $852mn to $3.46bn in the past year. Merus is a leader in developing multispecific antibodies with promising lead candidates petosemtamab and zenocutuzumab targeting various cancers. Merus has strong financials, and partnerships with major companies like Gilead, Incyte, and Eli Lilly, but faces risks due to its current valuation and assumptions about pipeline success.
Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC
Petosemtamab 1500 mg Q2W confirmed for both 2/3L phase 3 trial (LiGeR-HN2) and 1L trial (LiGeR-HN1) in r/m HNSCC following FDA feedback Petosemtamab 1500 mg Q2W confirmed for both 2/3L phase 3 trial (LiGeR-HN2) and 1L trial (LiGeR-HN1) in r/m HNSCC following FDA feedback
Merus' MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of a poster regarding MCLA-129 presented at the 2024 American Society of Clinical Oncology® (ASCO®) Annual Meeting taking place in Chicago May 31-June 4, 2024.
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced updated interim clinical data on MCLA-145 monotherapy and in combination with pembrolizumab were presented at the 2024 American Society of Clinical Oncology® (ASCO®) Annual Meeting taking place in Chicago May 31-June 4, 2024.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for MRUS.